Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 injection plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (Phase III, Stage 1)
CTR20241042Phase 3Active
- Sponsor
- Shangjian Bio
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SG301 in multiple myeloma (MM), sponsored by Shangjian Bio. Started Jun 2024; status: active.
02
Drugs
SG301
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241042.